{"schema_version":"secwatch.filing_event.v1","accession":"0001404644-24-000103","form_type":"8-K","ticker":"NGNE","cik":"0001404644","company_name":"Neurogene Inc.","filed_at":"2024-11-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.357471+00:00","generated_at":"2026-05-29T22:57:25.502374+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Neurogene Q3 net loss $20.2M; positive NGN-401 data; $200M private placement","bullets":["Q3 net loss $20.2M vs $14.6M YoY; cash & investments $139M as of Sep 30, 2024.","First 4 NGN-401 participants at 1E15 vg showed consistent improvements; 28-52% RSBQ improvement.","SAE at 3E15 vg dose; FDA allows continued enrollment at 1E15 vg; enrollment paused for protocol revision.","NGN-101 CLN5 Batten program discontinued after RMAT application denied; options being evaluated.","Closed ~$200M private placement extending cash runway into second half of 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001404644-24-000103","json":"https://secwatch.observer/filing/0001404644-24-000103.json","markdown":"https://secwatch.observer/filing/0001404644-24-000103.md","text":"https://secwatch.observer/filing/0001404644-24-000103.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404644/000140464424000103/0001404644-24-000103-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404644/000140464424000103/ngne-20241118.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T22:57:25.502374+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}